Alkem Laboratories Limited

BSE: 539523 NSE: ALKEM
Alkem Laboratories Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L00305MH1973PLC174201 Incorporated 08 August 1973 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: ALKEM · BSE: 539523 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹14,712 Cr
▲ 13.48% YoY
Computed EBITDA · FY 2026
₹3,588.56 Cr
▲ 19.38% YoY
Net profit · FY 2026
₹2,351.16 Cr
▲ 6.13% YoY
Authorised capital
₹50 Cr
Registered with MCA
Paid-up capital
₹23.91 Cr
Issued & subscribed
Open charges
₹1,085.77 Cr
Satisfied ₹4,919.56 Cr
Company age
53 yrs
Est. 1973
Employees · EPFO
18,498
Latest available

About Alkem Laboratories Limited

Data last updated: 14 July 2026

Alkem Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 08 August 1973, the company has been in operation for over 53 years.

Registered with ROC Mumbai under CIN L00305MH1973PLC174201. Listed on BSE: 539523 and NSE: ALKEM.

Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹23.91 Cr. Formerly known as Alkem Laboratories Private Limited. It is led by directors including Sandeep Singh and Sujjain Suresh Talwar.

Last AGM: 25 August 2025. Financial statements filed for year ended 31 March 2025. Office: Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹14,712 Cr, a growth of 13.48% compared to the previous year. The net worth stands at ₹14,349 Cr (up 15.4% YoY). Total assets are valued at ₹20,873 Cr (up 17.99% YoY).

The company has a workforce of approximately 18,498 employees as per the latest available data. Its group structure includes 5 subsidiaries.

The company is associated with 4 brands - Connect2clinic, Alkem Laboratories Ltd, Enzene Biosciences, Alkem Laboratories. As per MCA filings, the company has open charges of ₹1,085.77 Cr and satisfied charges of ₹4,919.56 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alkemlabs.com.

Company Details of Alkem Laboratories Limited
CIN L00305MH1973PLC174201
Registration Number 174201
Incorporation Date 08 August 1973
ROC Mumbai
Listing Status Listed (BSE: 539523, NSE: ALKEM)
Company Status Active
Date of Last AGM 25 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Vikas Gupta Ceo Sandeep Singh Managing Director Srinivas Balmiki Prasad Singh Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    alkemlabs.com
  • Social Media
  • Registered Address
    Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013
  • Industry
    Pharma, Drug Formulation & Development
Company report
Alkem Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Alkem Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Alkem Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Alkem Laboratories Limited

Alkem Laboratories Limited has one previous CIN (Corporate Identification Number): U00305MH1973PLC174201. The current CIN is L00305MH1973PLC174201, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L00305MH1973PLC174201 Current
U00305MH1973PLC174201 Previous

Associated Brands with Alkem Laboratories Limited

Alkem Laboratories Limited operates multiple associated brands including Connect2Clinic, Alkem Laboratories Ltd, and Enzene Biosciences. These brands represent Alkem Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Connect2Clinic
Provides comprehensive teleconsultation solutions for patients and healthcare professionals. connect2clinic.com
Enzene Biosciences
Company specializing in development of Biosimilars enzene.com
Alkem Laboratories
Pharmaceutical generics, formulations, and nutraceuticals are manufactured for therapeutic segments. alkemlabs.com
Alkem Laboratories Ltd
Production of FOS and related dietary fibers for food and health applications in India. foshealth.in

Competitors & Alternatives of Alkem Laboratories Limited

Brands and companies operating in the same space as Alkem Laboratories Limited include Mosaic Wellness, DocsApp, MyHealthcare and 7 more.

Competitor Description Location Founded
Mosaic Wellness Mosaic Wellness Provider of digital health coaching platforms for men, women, and parents Mumbai, India, India 2019
DocsApp DocsApp Chat-based mobile app for doctor teleconsultations is provided to patients. Bengaluru, India, India 2012
MyHealthcare MyHealthcare Provider of comprehensive digital healthcare ecosystem Gurugram, India, India 2017
Hybio Pharmaceutical Hybio Pharmaceutical Polypeptide drugs and APIs are developed and manufactured. Shenzhen, China, China 1998
MediAngels MediAngels Online telemedicine platform for specialist consultation and second opinion Mumbai, India, India 2009
Bajaj Finserv Health Bajaj Finserv Health Provides online doctor consultations, lab bookings, and medicine ordering services. Pune, India, India 2019
PolyPeptide PolyPeptide Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs. Baar, Switzerland, Switzerland 1952
AmbioPharm AmbioPharm CDMO and analytical services for peptide development are provided. North Augusta, United States, United States 2006
Mojocare Mojocare Personalized wellness solutions are delivered via a digital healthcare platform. Bengaluru, India, India 2020
vivitide vivitide Drug development services for neoantigen peptides and antibodies are provided. Gardner, United States, United States 1983

Business Activity of Alkem Laboratories Limited

Alkem Laboratories Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
G Trade G1 Wholesale Trading Locked
Premium access

Business activity turnover details for Alkem Laboratories Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Alkem Laboratories Limited

Alkem Laboratories Limited is audited by Deloitte Haskins and Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Deloitte Haskins and Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors and KMP of Alkem Laboratories Limited

Alkem Laboratories Limited currently reports 12 directors and 3 key managerial personnel. 17 former directors have served the organization.

Current Directors and KMP
Name Designation Appointment Date Tenure Status
Sandeep Singh
Also directs: Alkem Medtech Private Limited, Connect 2 Clinic Private Limited, Alkem Foundation and 5 more
Managing Director 09 Aug 2013 13 Years 0 Months Current
Manish Narang
Also directs: Alkem Medtech Private Limited, Travelon Services Private Limited
Company Secretary 16 Dec 2006 19 Years 8 Months Current
Sujjain Suresh Talwar
Also directs: Elantas Beck India Limited, Carborundum Universal Limited, Integrated Mumbai Business Park (India) Private Limited and 2 more
Director 05 Aug 2022 4 Years 0 Months Current
Srinivas Balmiki Prasad Singh
Also directs: Alkem Foundation, Alixer Nexgen Therapeutics Limited
Whole-Time Director 14 Sep 2022 3 Years 11 Months Current
Basudeo Narayan Singh
Also directs: Alkem Medtech Private Limited, Amplira Ventures Llp, Connect 2 Clinic Private Limited
Whole-Time Director 08 Aug 1973 53 Years 0 Months Current
Mritunjay Kumar Singh
Also directs: Indchemie Health Specialities Private Limited, Connect 2 Clinic Private Limited, Alkem Foundation
Whole-Time Director 11 Feb 2008 18 Years 6 Months Current
Showing 6 of 15 current directors and KMP. View all directors and KMP

Financials of Alkem Laboratories Limited FY 2026 filings available

Alkem Laboratories Limited reported revenue of ₹14,712 Cr (up 13.48% YoY) for FY 2026.

Revenue · FY 2026
₹14,712 Cr ▲ 13.48%
Profit · FY 2026
₹2,351.16 Cr ▲ 6.13%
Computed EBITDA · FY 2026
₹3,588.56 Cr ▲ 19.38%
Revenue₹ Cr · Consolidated05,00010,00015,000FY 2020: ₹8,344 Cr8,344FY 2020FY 2022: ₹10,634 Cr · +27.4% YoY10,634+27.4%FY 2022FY 2023: ₹11,599 Cr · +9.1% YoY11,599+9.1%FY 2023FY 2024: ₹12,668 Cr · +9.2% YoY12,668+9.2%FY 2024FY 2025: ₹12,965 Cr · +2.3% YoY12,965+2.3%FY 2025FY 2026: ₹14,712 Cr · +13.5% YoY14,712+13.5%FY 2026
Net Profit₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹1,149 Cr1,149FY 2020FY 2022: ₹1,680 Cr · +46.2% YoY1,680+46.2%FY 2022FY 2023: ₹1,007 Cr · -40.1% YoY1,007-40.1%FY 2023FY 2024: ₹1,811 Cr · +79.9% YoY1,811+79.9%FY 2024FY 2025: ₹2,215 Cr · +22.3% YoY2,215+22.3%FY 2025FY 2026: ₹2,351 Cr · +6.1% YoY2,351+6.1%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02,0004,0006,000Q1'25: ₹3,032 Cr · +2.2% YoY3,032+2.2%Q1'25Q2'25: ₹3,415 Cr · -0.7% YoY3,415-0.7%Q2'25Q3'25: ₹3,374 Cr · +1.5% YoY3,374+1.5%Q3'25Q4'25: ₹3,144 Cr · +7.1% YoY3,144+7.1%Q4'25Q1'26: ₹3,371 Cr · +11.2% YoY3,371+11.2%Q1'26Q2'26: ₹4,001 Cr · +17.2% YoY4,001+17.2%Q2'26Q3'26: ₹3,737 Cr · +10.7% YoY3,737+10.7%Q3'26Q4'26: ₹3,603 Cr · +14.6% YoY3,603+14.6%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Revenue from Operations ₹14,712 Cr ₹12,965 Cr ₹12,668 Cr ₹11,599 Cr ₹10,634 Cr ₹8,344.36 Cr
Other Income ₹583.35 Cr ₹493.74 Cr ₹310.84 Cr ₹216.08 Cr ₹162.65 Cr ₹104.22 Cr
Total Income ₹15,296 Cr ₹13,458 Cr ₹12,978 Cr ₹11,815 Cr ₹10,797 Cr ₹8,448.58 Cr
Cost of Materials Consumed ₹3,565.39 Cr ₹3,440.37 Cr ₹3,294.59 Cr ₹3,056.92 Cr ₹3,226.06 Cr ₹2,131.83 Cr
Purchases of Stock-in-Trade ₹1,694.5 Cr ₹1,514.02 Cr ₹1,628.87 Cr ₹1,387.55 Cr ₹1,489.71 Cr ₹1,443.06 Cr
Changes in Inventories -₹167.12 Cr -₹190.13 Cr ₹14.12 Cr ₹462.37 Cr -₹535.48 Cr -₹229.95 Cr
Employee Benefit Expense ₹2,837.11 Cr ₹2,453.92 Cr ₹2,201.01 Cr ₹2,131.35 Cr ₹1,962.71 Cr ₹1,505.49 Cr
Finance Costs ₹160.78 Cr ₹121.7 Cr ₹112.41 Cr ₹107.36 Cr ₹52.37 Cr ₹65.06 Cr
Depreciation & Amortisation ₹382.06 Cr ₹357.16 Cr ₹299.3 Cr ₹310.42 Cr ₹303.96 Cr ₹252.76 Cr
Other Expenses ₹3,777.18 Cr ₹3,234.19 Cr ₹3,283.5 Cr ₹2,951.62 Cr ₹2,438.27 Cr ₹2,020.54 Cr
Total Expenses ₹12,250 Cr ₹10,931 Cr ₹10,834 Cr ₹10,408 Cr ₹8,937.6 Cr ₹7,188.79 Cr
Profit Before Exceptional Items & Tax ₹3,045.72 Cr ₹2,527.03 Cr ₹2,144.62 Cr ₹1,407.75 Cr ₹1,859.24 Cr ₹1,259.79 Cr
Exceptional Items -₹174.83 Cr ₹0 -₹121.49 Cr -₹102.98 Cr -₹14.96 Cr ₹0
Profit Before Tax ₹2,870.89 Cr ₹2,527.03 Cr ₹2,023.13 Cr ₹1,304.77 Cr ₹1,844.28 Cr ₹1,259.79 Cr
Total Tax Expense ₹517.76 Cr ₹311.03 Cr ₹211.67 Cr ₹297.96 Cr ₹163.96 Cr ₹110.48 Cr
Net Profit ₹2,351.16 Cr ₹2,215.38 Cr ₹1,811.46 Cr ₹1,006.81 Cr ₹1,680.32 Cr ₹1,149.31 Cr
  attributable to Owners ₹2,301.8 Cr ₹2,165.48 Cr ₹1,795.77 Cr ₹984.17 Cr ₹1,645.62 Cr ₹1,127.07 Cr
  attributable to NCI ₹49.36 Cr ₹49.9 Cr ₹15.69 Cr ₹22.64 Cr ₹34.7 Cr ₹22.24 Cr
Other Comprehensive Income ₹183.79 Cr ₹19.72 Cr ₹20.04 Cr ₹114.9 Cr ₹34.14 Cr ₹26.86 Cr
Total Comprehensive Income ₹2,534.95 Cr ₹2,235.1 Cr ₹1,831.5 Cr ₹1,121.71 Cr ₹1,714.46 Cr ₹1,176.17 Cr
EBITDA (computed) ₹3,588.56 Cr ₹3,005.89 Cr ₹2,556.33 Cr ₹1,825.53 Cr ₹2,215.57 Cr ₹1,577.61 Cr
Basic EPS ₹192.51 ₹181.11 ₹150.19 ₹82.31 ₹137.63 ₹94.26
Diluted EPS ₹192.51 ₹181.11 ₹150.19 ₹82.31 ₹137.63 ₹94.26
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹20,873 Cr ₹17,691 Cr ₹15,575 Cr ₹13,757 Cr
Non-current Assets ₹8,662.45 Cr ₹6,745.28 Cr ₹5,163.32 Cr ₹5,026.97 Cr
Current Assets ₹12,211 Cr ₹10,811 Cr ₹10,412 Cr ₹8,606.42 Cr
Property, Plant & Equipment ₹2,694.97 Cr ₹2,063.93 Cr ₹2,161.46 Cr ₹2,065.4 Cr
Inventories ₹3,333.22 Cr ₹2,922.41 Cr ₹2,661.18 Cr ₹2,607.53 Cr
Trade Receivables ₹2,979.11 Cr ₹2,466.25 Cr ₹2,252.81 Cr ₹2,132.18 Cr
Cash & Equivalents ₹247.91 Cr ₹304.14 Cr ₹455.07 Cr ₹273.8 Cr
Equity (Net Worth) ₹14,349 Cr ₹12,434 Cr ₹10,714 Cr ₹9,435 Cr
Equity Share Capital ₹23.91 Cr ₹23.91 Cr ₹23.91 Cr ₹23.91 Cr
Borrowings (Non-current) ₹492.45 Cr ₹310.91 Cr ₹40 Cr ₹70.33 Cr
Borrowings (Current) ₹1,131.05 Cr ₹751.88 Cr ₹1,173.97 Cr ₹1,326.35 Cr
Total Debt (computed) ₹1,623.5 Cr ₹1,062.79 Cr ₹1,213.97 Cr ₹1,396.68 Cr
Current Liabilities ₹4,782.7 Cr ₹3,958.69 Cr ₹3,994.55 Cr ₹3,707.15 Cr
Total Liabilities ₹6,524.04 Cr ₹5,257.47 Cr ₹4,860.5 Cr ₹4,321.65 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,963.03 Cr ₹1,912.84 Cr ₹1,948.08 Cr ₹1,682.5 Cr ₹1,111.02 Cr
Investing Cash Flow -₹1,667.21 Cr -₹1,298.76 Cr -₹1,008.51 Cr ₹112.84 Cr -₹1,435.13 Cr
Financing Cash Flow -₹503.4 Cr -₹810.99 Cr -₹1,145.01 Cr -₹1,760.82 Cr ₹379.57 Cr
Capital Expenditure ₹617.26 Cr ₹675.62 Cr ₹259.29 Cr ₹232.91 Cr ₹338.88 Cr
Free Cash Flow (computed) ₹1,345.77 Cr ₹1,237.22 Cr ₹1,688.79 Cr ₹1,449.59 Cr ₹772.14 Cr
Dividends Paid ₹613.7 Cr ₹504.62 Cr ₹540.49 Cr ₹529.52 Cr ₹421.91 Cr
Net Change in Cash -₹222.04 Cr -₹186.4 Cr -₹207.49 Cr ₹41.62 Cr ₹57.96 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹3,603.32 Cr ₹3,736.82 Cr ₹4,000.99 Cr ₹3,371.14 Cr ₹3,143.75 Cr ₹3,374.28 Cr ₹3,414.67 Cr ₹3,031.82 Cr ₹2,935.82 Cr ₹3,323.87 Cr ₹3,440.17 Cr ₹2,967.72 Cr
Other Income ₹200.07 Cr ₹143.1 Cr ₹103.69 Cr ₹136.49 Cr ₹145.96 Cr ₹92.99 Cr ₹134.48 Cr ₹120.31 Cr ₹88.17 Cr ₹93.64 Cr ₹63.19 Cr ₹65.84 Cr
Total Income ₹3,803.39 Cr ₹3,879.92 Cr ₹4,104.68 Cr ₹3,507.63 Cr ₹3,289.71 Cr ₹3,467.27 Cr ₹3,549.15 Cr ₹3,152.13 Cr ₹3,023.99 Cr ₹3,417.51 Cr ₹3,503.36 Cr ₹3,033.56 Cr
Cost of Materials Consumed ₹894.94 Cr ₹937.77 Cr ₹905.57 Cr ₹827.11 Cr ₹777.03 Cr ₹924.01 Cr ₹902.17 Cr ₹837.16 Cr ₹798.76 Cr ₹838.54 Cr ₹824.71 Cr ₹832.58 Cr
Purchases of Stock-in-Trade ₹497.77 Cr ₹327.96 Cr ₹471.57 Cr ₹397.2 Cr ₹379.96 Cr ₹397.48 Cr ₹353.92 Cr ₹382.66 Cr ₹380.7 Cr ₹460.81 Cr ₹431.89 Cr ₹355.47 Cr
Changes in Inventories -₹144.84 Cr ₹6.98 Cr ₹23.89 Cr -₹53.15 Cr ₹122.29 Cr -₹117.16 Cr -₹51.39 Cr -₹143.87 Cr -₹72.06 Cr ₹5.19 Cr ₹70.47 Cr ₹10.52 Cr
Employee Benefit Expense ₹712.1 Cr ₹721.51 Cr ₹710.25 Cr ₹693.25 Cr ₹616.35 Cr ₹624.81 Cr ₹610.49 Cr ₹602.27 Cr ₹505.83 Cr ₹572.15 Cr ₹555.38 Cr ₹567.65 Cr
Finance Costs ₹53.88 Cr ₹42.1 Cr ₹35.02 Cr ₹29.78 Cr ₹28.42 Cr ₹36.03 Cr ₹28.14 Cr ₹29.11 Cr ₹26.86 Cr ₹25.46 Cr ₹30.32 Cr ₹29.77 Cr
Depreciation & Amortisation ₹105.76 Cr ₹95.01 Cr ₹93.61 Cr ₹87.68 Cr ₹112.49 Cr ₹85.28 Cr ₹78.91 Cr ₹80.48 Cr ₹83.43 Cr ₹69.56 Cr ₹73.9 Cr ₹72.41 Cr
Other Expenses ₹1,125.96 Cr ₹914.6 Cr ₹968.94 Cr ₹767.68 Cr ₹856.83 Cr ₹785.75 Cr ₹846.65 Cr ₹744.96 Cr ₹920.61 Cr ₹739.59 Cr ₹810.99 Cr ₹812.31 Cr
Total Expenses ₹3,245.57 Cr ₹3,045.93 Cr ₹3,208.85 Cr ₹2,749.55 Cr ₹2,893.37 Cr ₹2,736.2 Cr ₹2,768.89 Cr ₹2,532.77 Cr ₹2,644.13 Cr ₹2,711.3 Cr ₹2,797.66 Cr ₹2,680.71 Cr
Profit Before Exceptional Items & Tax ₹557.82 Cr ₹833.99 Cr ₹895.83 Cr ₹758.08 Cr ₹396.34 Cr ₹731.07 Cr ₹780.26 Cr ₹619.36 Cr ₹379.86 Cr ₹706.21 Cr ₹705.7 Cr ₹352.85 Cr
Exceptional Items -₹134.97 Cr -₹52.79 Cr ₹0 ₹12.93 Cr ₹0 ₹0 ₹0 ₹0 -₹12.52 Cr -₹51.31 Cr -₹57.66 Cr ₹0
Profit Before Tax ₹422.85 Cr ₹781.2 Cr ₹895.83 Cr ₹771.01 Cr ₹396.34 Cr ₹731.07 Cr ₹780.26 Cr ₹619.36 Cr ₹367.34 Cr ₹654.9 Cr ₹648.04 Cr ₹352.85 Cr
Total Tax Expense ₹171.17 Cr ₹127.67 Cr ₹116.23 Cr ₹102.69 Cr ₹73.33 Cr ₹90.28 Cr ₹78.3 Cr ₹69.12 Cr ₹62.86 Cr ₹50.62 Cr ₹33.15 Cr ₹65.04 Cr
Net Profit ₹251.11 Cr ₹653.03 Cr ₹779.11 Cr ₹667.91 Cr ₹322.39 Cr ₹640.79 Cr ₹701.96 Cr ₹550.24 Cr ₹304.48 Cr ₹604.28 Cr ₹614.89 Cr ₹287.81 Cr
  attributable to Owners ₹236.46 Cr ₹636.02 Cr ₹765.06 Cr ₹664.26 Cr ₹305.86 Cr ₹625.82 Cr ₹688.64 Cr ₹545.16 Cr ₹293.56 Cr ₹594.96 Cr ₹620.52 Cr ₹286.73 Cr
  attributable to NCI ₹14.65 Cr ₹17.01 Cr ₹14.05 Cr ₹3.65 Cr ₹16.53 Cr ₹14.97 Cr ₹13.32 Cr ₹5.08 Cr ₹10.92 Cr ₹9.32 Cr -₹5.63 Cr ₹1.08 Cr
Other Comprehensive Income ₹115.27 Cr ₹23.57 Cr ₹42.87 Cr ₹2.08 Cr -₹2.59 Cr ₹12.1 Cr ₹6.1 Cr ₹4.11 Cr -₹7.65 Cr ₹5.48 Cr ₹10.99 Cr ₹11.22 Cr
Total Comprehensive Income ₹366.38 Cr ₹676.6 Cr ₹821.98 Cr ₹669.99 Cr ₹319.8 Cr ₹652.89 Cr ₹708.06 Cr ₹554.35 Cr ₹296.83 Cr ₹609.76 Cr ₹625.88 Cr ₹299.03 Cr
EBITDA (computed) ₹717.46 Cr ₹971.1 Cr ₹1,024.46 Cr ₹875.54 Cr ₹537.25 Cr ₹852.38 Cr ₹887.31 Cr ₹728.95 Cr ₹490.15 Cr ₹801.23 Cr ₹809.92 Cr ₹455.03 Cr
Basic EPS ₹19.77 ₹53.19 ₹63.99 ₹55.56 ₹25.57 ₹52.34 ₹57.60 ₹45.60 ₹24.55 ₹49.76 ₹51.90 ₹23.98
Diluted EPS ₹19.77 ₹53.19 ₹63.99 ₹55.56 ₹25.57 ₹52.34 ₹57.60 ₹45.60 ₹24.55 ₹49.76 ₹51.90 ₹23.98
Latest 12 quarters shown of 23 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹9,663.91 Cr ₹8,813.44 Cr ₹9,747.72 Cr ₹9,054.55 Cr ₹8,829.81 Cr ₹7,219.68 Cr ₹6,677.08 Cr
Other Income ₹555.17 Cr ₹507.06 Cr ₹305.99 Cr ₹266.29 Cr ₹199.89 Cr ₹190.01 Cr ₹95.98 Cr
Total Income ₹10,219 Cr ₹9,320.5 Cr ₹10,054 Cr ₹9,320.84 Cr ₹9,029.7 Cr ₹7,409.69 Cr ₹6,773.06 Cr
Cost of Materials Consumed ₹2,429.33 Cr ₹2,395.92 Cr ₹2,749.93 Cr ₹2,629.78 Cr ₹2,849.75 Cr ₹2,046.52 Cr ₹1,799.87 Cr
Purchases of Stock-in-Trade ₹426.95 Cr ₹389.61 Cr ₹1,128.7 Cr ₹943.13 Cr ₹1,077.04 Cr ₹919.79 Cr ₹784.38 Cr
Changes in Inventories -₹45.67 Cr ₹56.61 Cr -₹71.31 Cr ₹257.73 Cr -₹360.9 Cr -₹301.29 Cr -₹33.69 Cr
Employee Benefit Expense ₹1,883.03 Cr ₹1,630.96 Cr ₹1,560.28 Cr ₹1,516.22 Cr ₹1,434.49 Cr ₹1,158.72 Cr ₹1,066.76 Cr
Finance Costs ₹57.29 Cr ₹76.11 Cr ₹81.91 Cr ₹86.4 Cr ₹37.9 Cr ₹42.93 Cr ₹38.71 Cr
Depreciation & Amortisation ₹256.56 Cr ₹283.61 Cr ₹244.35 Cr ₹229.85 Cr ₹218.98 Cr ₹198.93 Cr ₹186.84 Cr
Other Expenses ₹2,545.88 Cr ₹2,184.14 Cr ₹2,414.99 Cr ₹2,330.74 Cr ₹2,019.07 Cr ₹1,447.01 Cr ₹1,592.11 Cr
Total Expenses ₹7,553.37 Cr ₹7,016.96 Cr ₹8,108.85 Cr ₹7,993.85 Cr ₹7,276.33 Cr ₹5,512.61 Cr ₹5,434.98 Cr
Profit Before Exceptional Items & Tax ₹2,665.71 Cr ₹2,303.54 Cr ₹1,944.86 Cr ₹1,326.99 Cr ₹1,753.37 Cr ₹1,897.08 Cr ₹1,338.08 Cr
Exceptional Items -₹143.09 Cr ₹0 -₹63.83 Cr ₹0 ₹0 -₹12.78 Cr ₹0
Profit Before Tax ₹2,522.62 Cr ₹2,303.54 Cr ₹1,881.03 Cr ₹1,326.99 Cr ₹1,753.37 Cr ₹1,884.3 Cr ₹1,338.08 Cr
Total Tax Expense ₹337.5 Cr ₹213.82 Cr ₹133.88 Cr ₹192.52 Cr ₹212.12 Cr ₹199.22 Cr ₹73.66 Cr
Net Profit ₹2,282.09 Cr ₹2,280.89 Cr ₹1,747.15 Cr ₹1,134.47 Cr ₹1,541.25 Cr ₹1,685.08 Cr ₹1,264.42 Cr
Other Comprehensive Income ₹4.62 Cr -₹11.5 Cr -₹4.35 Cr -₹2.19 Cr -₹4.86 Cr -₹4.99 Cr -₹17.28 Cr
Total Comprehensive Income ₹2,286.71 Cr ₹2,269.39 Cr ₹1,742.8 Cr ₹1,132.28 Cr ₹1,536.39 Cr ₹1,680.09 Cr ₹1,247.14 Cr
EBITDA (computed) ₹2,979.56 Cr ₹2,663.26 Cr ₹2,271.12 Cr ₹1,643.24 Cr ₹2,010.25 Cr ₹2,138.94 Cr ₹1,563.63 Cr
Basic EPS ₹182.76 ₹174.78 ₹146.13 ₹94.88 ₹128.90 ₹140.93 ₹105.75
Diluted EPS ₹182.76 ₹174.78 ₹146.13 ₹94.88 ₹128.90 ₹140.93 ₹105.75
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹17,261 Cr ₹15,596 Cr ₹14,038 Cr ₹12,731 Cr
Non-current Assets ₹9,431.01 Cr ₹7,247.53 Cr ₹5,997.72 Cr ₹5,959.01 Cr
Current Assets ₹7,830.12 Cr ₹7,354 Cr ₹8,040.08 Cr ₹6,772.21 Cr
Property, Plant & Equipment ₹1,422.39 Cr ₹1,482.37 Cr ₹1,659.67 Cr ₹1,672.52 Cr
Inventories ₹1,631.76 Cr ₹1,522.9 Cr ₹1,849.56 Cr ₹1,724.66 Cr
Trade Receivables ₹1,567.24 Cr ₹1,559.84 Cr ₹1,753.64 Cr ₹1,768.34 Cr
Cash & Equivalents ₹65.45 Cr ₹74.92 Cr ₹38.95 Cr ₹5.01 Cr
Equity (Net Worth) ₹13,999 Cr ₹12,322 Cr ₹10,555 Cr ₹9,349.85 Cr
Equity Share Capital ₹23.91 Cr ₹23.91 Cr ₹23.91 Cr ₹23.91 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹45.06 Cr
Borrowings (Current) ₹539.24 Cr ₹371.24 Cr ₹957.23 Cr ₹1,136.63 Cr
Total Debt (computed) ₹539.24 Cr ₹371.24 Cr ₹957.23 Cr ₹1,181.69 Cr
Current Liabilities ₹2,746.81 Cr ₹2,543.44 Cr ₹3,106.4 Cr ₹3,044.83 Cr
Total Liabilities ₹3,262.37 Cr ₹3,273.77 Cr ₹3,483.19 Cr ₹3,381.37 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,969.12 Cr ₹2,189.41 Cr ₹1,686.56 Cr ₹1,437.42 Cr ₹1,299.34 Cr
Investing Cash Flow -₹1,461.25 Cr -₹1,007.41 Cr -₹865.61 Cr ₹197.04 Cr -₹1,669.34 Cr
Financing Cash Flow -₹672.82 Cr -₹1,036.89 Cr -₹959.04 Cr -₹1,711.27 Cr ₹436.59 Cr
Capital Expenditure ₹277.27 Cr ₹226.2 Cr ₹106.68 Cr ₹141.78 Cr ₹244.87 Cr
Free Cash Flow (computed) ₹1,691.85 Cr ₹1,963.21 Cr ₹1,579.88 Cr ₹1,295.64 Cr ₹1,054.46 Cr
Dividends Paid ₹609.78 Cr ₹502.17 Cr ₹538.04 Cr ₹526.09 Cr ₹418.48 Cr
Net Change in Cash -₹164.95 Cr ₹145.11 Cr -₹138.09 Cr -₹76.81 Cr ₹66.59 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,258.44 Cr ₹2,491.27 Cr ₹2,542.03 Cr ₹2,372.17 Cr ₹2,044.94 Cr ₹2,286.83 Cr ₹2,871.97 Cr ₹2,500.1 Cr ₹2,365.37 Cr ₹2,494.59 Cr ₹2,634.59 Cr ₹2,253.17 Cr
Other Income ₹205.69 Cr ₹131.53 Cr ₹101.37 Cr ₹116.58 Cr ₹111.59 Cr ₹169.18 Cr ₹120.19 Cr ₹106.1 Cr ₹83.79 Cr ₹95.66 Cr ₹61.84 Cr ₹64.7 Cr
Total Income ₹2,464.13 Cr ₹2,622.8 Cr ₹2,643.4 Cr ₹2,488.75 Cr ₹2,156.53 Cr ₹2,456.01 Cr ₹2,992.16 Cr ₹2,606.2 Cr ₹2,449.16 Cr ₹2,590.25 Cr ₹2,696.43 Cr ₹2,317.87 Cr
Cost of Materials Consumed ₹658.86 Cr ₹587.51 Cr ₹567.63 Cr ₹615.33 Cr ₹451.41 Cr ₹693.13 Cr ₹732.29 Cr ₹761.23 Cr ₹652.71 Cr ₹700.73 Cr ₹707.12 Cr ₹689.37 Cr
Purchases of Stock-in-Trade ₹107.5 Cr ₹113.1 Cr ₹122.84 Cr ₹83.51 Cr ₹85.24 Cr ₹120.9 Cr ₹315.4 Cr ₹207.36 Cr ₹269.96 Cr ₹331.18 Cr ₹282.39 Cr ₹245.17 Cr
Changes in Inventories -₹66.67 Cr ₹15.67 Cr -₹2.6 Cr ₹7.93 Cr ₹187.14 Cr -₹88.15 Cr ₹39.37 Cr -₹85.66 Cr ₹8.67 Cr -₹27.41 Cr ₹10.66 Cr -₹63.23 Cr
Employee Benefit Expense ₹466.86 Cr ₹485.58 Cr ₹460.85 Cr ₹469.74 Cr ₹401.63 Cr ₹418.48 Cr ₹429.76 Cr ₹425.9 Cr ₹343.41 Cr ₹407.63 Cr ₹395.18 Cr ₹414.06 Cr
Finance Costs ₹16.24 Cr ₹15.51 Cr ₹12.75 Cr ₹12.79 Cr ₹16.91 Cr ₹21 Cr ₹17.57 Cr ₹21.44 Cr ₹20.68 Cr ₹21.11 Cr ₹18.7 Cr ₹21.42 Cr
Depreciation & Amortisation ₹78.17 Cr ₹60.91 Cr ₹58.59 Cr ₹58.89 Cr ₹91.64 Cr ₹67.61 Cr ₹62.59 Cr ₹64.35 Cr ₹69.1 Cr ₹58.12 Cr ₹59.02 Cr ₹58.11 Cr
Other Expenses ₹747.87 Cr ₹600.2 Cr ₹622.63 Cr ₹575.18 Cr ₹622.73 Cr ₹484.64 Cr ₹627.51 Cr ₹570.64 Cr ₹683.1 Cr ₹513.2 Cr ₹584.64 Cr ₹634.05 Cr
Total Expenses ₹2,008.83 Cr ₹1,878.48 Cr ₹1,842.69 Cr ₹1,823.37 Cr ₹1,856.7 Cr ₹1,717.61 Cr ₹2,224.49 Cr ₹1,965.26 Cr ₹2,047.63 Cr ₹2,004.56 Cr ₹2,057.71 Cr ₹1,998.95 Cr
Profit Before Exceptional Items & Tax ₹455.3 Cr ₹744.32 Cr ₹800.71 Cr ₹665.38 Cr ₹299.83 Cr ₹738.4 Cr ₹767.67 Cr ₹640.94 Cr ₹401.53 Cr ₹585.69 Cr ₹638.72 Cr ₹318.92 Cr
Exceptional Items -₹119.21 Cr -₹38.17 Cr ₹0 ₹14.29 Cr ₹0 ₹0 ₹0 ₹0 -₹12.52 Cr -₹51.31 Cr ₹0 ₹0
Profit Before Tax ₹336.09 Cr ₹706.15 Cr ₹800.71 Cr ₹679.67 Cr ₹299.83 Cr ₹738.4 Cr ₹767.67 Cr ₹640.94 Cr ₹389.01 Cr ₹534.38 Cr ₹638.72 Cr ₹318.92 Cr
Total Tax Expense ₹119.03 Cr ₹84.01 Cr ₹77.05 Cr ₹57.41 Cr ₹73.95 Cr ₹62.17 Cr ₹70.09 Cr ₹57.69 Cr ₹64.04 Cr ₹30.15 Cr -₹7.79 Cr ₹47.48 Cr
Net Profit ₹217.06 Cr ₹622.14 Cr ₹786.73 Cr ₹656.16 Cr ₹276.94 Cr ₹723.12 Cr ₹697.58 Cr ₹583.25 Cr ₹324.97 Cr ₹504.23 Cr ₹646.51 Cr ₹271.44 Cr
Other Comprehensive Income ₹18.5 Cr -₹9.57 Cr -₹2.16 Cr -₹2.15 Cr -₹4.03 Cr -₹2.49 Cr -₹2.5 Cr -₹2.48 Cr ₹35 Lakh -₹1.56 Cr -₹1.57 Cr -₹1.57 Cr
Total Comprehensive Income ₹235.56 Cr ₹612.57 Cr ₹784.57 Cr ₹654.01 Cr ₹272.91 Cr ₹720.63 Cr ₹695.08 Cr ₹580.77 Cr ₹325.32 Cr ₹502.67 Cr ₹644.94 Cr ₹269.87 Cr
EBITDA (computed) ₹549.71 Cr ₹820.74 Cr ₹872.05 Cr ₹737.06 Cr ₹408.38 Cr ₹827.01 Cr ₹847.83 Cr ₹726.73 Cr ₹491.31 Cr ₹664.92 Cr ₹716.44 Cr ₹398.45 Cr
Basic EPS ₹18.16 ₹52.03 ₹60.53 ₹52.04 ₹18.89 ₹56.56 ₹58.34 ₹48.78 ₹27.18 ₹42.17 ₹54.07 ₹22.70
Diluted EPS ₹18.16 ₹52.03 ₹60.53 ₹52.04 ₹18.89 ₹56.56 ₹58.34 ₹48.78 ₹27.18 ₹42.17 ₹54.07 ₹22.70
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Alkem Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Alkem Laboratories Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.20%, foreign institutional investors hold 10.16%, domestic institutional investors hold 21.40%, retail and other public shareholders hold 17.25% of Alkem Laboratories Limited. The company had 62,835 shareholders on record.

Promoters: 51.20%DII (Domestic Institutional): 21.40%FII (Foreign Institutional): 10.16%Retail & Others: 17.25%
Mar 2026
QUARTER
51.20% Promoters
21.40% DII (Domestic Institutional)
10.16% FII (Foreign Institutional)
17.25% Retail & Others
Promoter holding - history
Now 51.20% · Mar 2026High 67.02% · Sep 2017Low 51.20% · Sep 2025
50%54.8%59.5%64.3%69%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 66.23%Mar 2016: 66.78%Jun 2016: 66.88%Sep 2016: 66.88%Dec 2016: 66.97%Mar 2017: 66.97%Jun 2017: 66.99%Sep 2017: 67.02%Dec 2017: 65.86%Mar 2018: 65.86%Jun 2018: 65.92%Sep 2018: 65.92%Dec 2018: 65.98%Mar 2019: 66.02%Jun 2019: 66.03%Sep 2019: 66.04%Dec 2019: 66.04%Mar 2020: 65.88%Jun 2020: 62.43%Sep 2020: 62.43%Dec 2020: 62.43%Mar 2021: 60.16%Jun 2021: 58.84%Sep 2021: 58.84%Dec 2021: 57.13%Mar 2022: 57.13%Jun 2022: 57.14%Sep 2022: 57.16%Dec 2022: 57.16%Mar 2023: 57.16%Jun 2023: 57.16%Sep 2023: 56.74%Dec 2023: 56.74%Mar 2024: 56.74%Jun 2024: 56.38%Sep 2024: 55.66%Dec 2024: 55.66%Mar 2025: 55.13%Jun 2025: 53.04%Sep 2025: 51.20%Dec 2025: 51.20%Mar 2026: 51.20%67.02%51.20%51.20%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters51.20%51.20%51.20%53.04%55.13%55.66%
Public48.80%48.80%48.80%46.96%44.87%44.34%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters51.20%55.13%56.74%57.16%57.13%60.16%65.88%66.02%65.86%66.97%66.78%
Public48.80%44.87%43.26%42.84%42.87%39.84%34.12%33.98%34.14%33.03%33.22%
Promoter change (YoY, %pts)-3.93-1.61-0.42+0.03-3.03-5.72-0.14+0.16-1.11+0.19-

Board & Governance of Alkem Laboratories Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Alkem Laboratories Limited has 12 directors - 6 independent and 6 executive. The board is chaired by Basudeo N. Singh.

DirectorPositionOn board sinceListed boards
Basudeo N. Singh Executive Director · Chairperson 1973-08-08 1
Sandeep Singh Executive Director · MD 2013-08-09 1
Mritunjay Kumar Singh Executive Director 2008-02-11 1
Madhurima Singh Executive Director 2021-12-20 1
Sarvesh Singh Executive Director 2019-11-11 1
Srinivas Singh Executive Director 2022-09-14 1
Narendra Aneja Non-Executive - Independent Director 2020-03-16 1
Sujjain Talwar Non-Executive - Independent Director 2022-08-05 3
Rajeev Kher Non-Executive - Independent Director 2024-08-09 2
Laxmana Ranjal Shenoy Non-Executive - Independent Director 2025-07-13 1
Neela Bhattacherjee Non-Executive - Independent Director 2025-07-13 2
Diwakar Gupta Non-Executive - Independent Director 2025-07-13 3
Board Committees
CommitteeMembers
Audit Committee Narendra Aneja (Chairperson), Sandeep Singh, Mritunjay Kumar Singh, Laxmana Ranjal Shenoy, Rajeev Kher, Diwakar Gupta
Nomination and remuneration committee Laxmana Ranjal Shenoy (Chairperson), Basudeo N. Singh, Neela Bhattacherjee, Sujjain Talwar
Stakeholders Relationship Committee Sujjain Talwar (Chairperson), Mritunjay Kumar Singh, Madhurima Singh, Srinivas Singh
Risk Management Committee Mritunjay Kumar Singh (Chairperson), Sandeep Singh, Srinivas Singh, Laxmana Ranjal Shenoy, Diwakar Gupta, Neela Bhattacherjee
Corporate Social Responsibility Committee Madhurima Singh (Chairperson), Srinivas Singh, Rajeev Kher, Narendra Aneja, Sarvesh Singh

Group Structure of Alkem Laboratories Limited

Alkem Laboratories Limited has 5 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Alkem Laboratories Limited's business expansion strategy and organizational complexity.

5
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Cachet Pharmaceuticals Private Limited U24230BR1978PTC001328 -
Indchemie Health Specialities Private Limited U24230MH1986PTC039692 -
Enzene Biosciences Limited U24232PN2006PLC165610 -
Alkem Foundation U85100MH2010NPL206161 -
Connect 2 Clinic Private Limited U93090MH2020PTC339772 -

Showing major subsidiaries. Total: 5.

Charges & Borrowings of Alkem Laboratories Limited

Open charges
₹1,085.77 Cr
Satisfied charges
₹4,919.56 Cr
Breakdown by lending institutions
Citi Bank N.A.₹341.96 Cr
Others₹288.00 Cr
Hdfc Bank Limited₹270.32 Cr
State Bank of India₹100.20 Cr
Bank of India₹85.00 Cr
Others₹0.30 Cr
Latest charge details
DateLenderAmountStatus
15 Jul 2024 Others ₹100 Cr Open
26 Feb 2024 Others ₹108 Cr Open
07 Oct 2023 Bank of India ₹85 Cr Open
24 Aug 2023 Others ₹80 Cr Open
27 Mar 2023 Hdfc Bank Limited ₹270.32 Cr Open

Total charge records: 46 View all charges

Employees and EPFO Compliance at Alkem Laboratories Limited

Alkem Laboratories Limited has a workforce of 18,498 employees as of Nov 19, 2024.

Employee count
18,498
Active EPFO establishments
1
Employee growth
0.34%
Premium access

Employee and EPFO history for Alkem Laboratories Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Alkem Laboratories Limited

Premium access

GST registrations and filing compliance for Alkem Laboratories Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Alkem Laboratories Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Alkem Laboratories Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Alkem Laboratories Limited

Premium access

MSME payment history for Alkem Laboratories Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Alkem Laboratories Limited

Premium access

Corporate group structure for Alkem Laboratories Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Alkem Laboratories Limited

Premium access

MCA filings and documents for Alkem Laboratories Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Alkem Laboratories Limited

Activity
25 Aug 2025
Alkem Laboratories Limited last Annual general meeting of members was held on 25 Aug 2025 as per latest MCA records.
Directors
13 Jul 2025
Laxmana Ranjal Shenoy was appointed as a Director on 13 Jul 2025 & has been associated with this company since 1 year 1 month.
Directors
13 Jul 2025
Neela Bhattacherjee was appointed as a Director on 13 Jul 2025 & has been associated with this company since 1 year 1 month.
Directors
13 Jul 2025
Diwakar Gupta was appointed as a Director on 13 Jul 2025 & has been associated with this company since 1 year 1 month.
Activity
31 Mar 2025
Alkem Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
09 Aug 2024
Rajeev Kher was appointed as a Director on 09 Aug 2024 & has been associated with this company since 2 years 12 days.

Recent News on Alkem Laboratories Limited

Stocks that will see action today: February 7, 2025
07 Feb 2025 · Thehindubusinessline

Frequently Asked Questions about Alkem Laboratories Limited

Alkem Laboratories Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 08 August 1973 (53+ years old) and is registered under CIN L00305MH1973PLC174201. Listed on BSE: 539523 and NSE: ALKEM. The company has 18,498 employees.

Alkem Laboratories Limited reported revenue of ₹14,712 Cr for FY 2026 (up 13.48% YoY) based on consolidated NSE filings.

The current directors and KMP of Alkem Laboratories Limited are:

The primary industry of Alkem Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Alkem Laboratories Limited is listed on both BSE (code: 539523) and NSE (symbol: ALKEM).

Alkem Laboratories Limited can be reached at the registered office: Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013, or through the website alkemlabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available